Published in Clin Pharmacol Ther on August 01, 2001
Pharmacogenetic Morphine Spine Study | NCT01839461
Patient Controlled Analgesia Pharmacogenetic Study | NCT01731873
Multicenter Perioperative Opioid Pharmacogenetic Study | NCT01495611
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res (2004) 1.65
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut (2003) 1.35
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet (2008) 1.33
Multifactorial etiology of gastric cancer. Methods Mol Biol (2012) 1.29
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics (2011) 1.29
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol (2002) 1.28
MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet (2003) 1.26
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer (2010) 1.20
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol (2006) 1.18
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res (2009) 1.17
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci (2010) 1.16
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol (2005) 1.15
Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol (2003) 1.14
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother (2009) 1.13
Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol (2005) 1.12
ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut (2003) 1.10
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs (2008) 1.08
P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother (2004) 1.06
The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol (2006) 1.05
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res (2013) 1.04
Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet (2007) 1.04
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs (2009) 1.03
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol (2006) 1.03
Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol (2011) 1.01
Improving the oral bioavailability of beneficial polyphenols through designed synergies. Genes Nutr (2009) 1.00
Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol (2012) 1.00
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol (2002) 0.99
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol (2011) 0.98
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol (2007) 0.98
Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut (2003) 0.98
ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol (2011) 0.98
Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol (2009) 0.98
The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int J Colorectal Dis (2007) 0.97
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol (2005) 0.96
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry (2012) 0.96
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol (2004) 0.95
CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit (2011) 0.93
Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci (2005) 0.93
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics (2007) 0.93
Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol (2008) 0.93
Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther (2008) 0.92
Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur J Clin Pharmacol (2007) 0.92
Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol (2004) 0.92
Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract (2009) 0.91
MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol (2006) 0.90
Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol (2008) 0.90
Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol (2006) 0.90
Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci (2002) 0.89
Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br J Clin Pharmacol (2014) 0.89
Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist (2011) 0.89
Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol (2010) 0.88
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer (2014) 0.87
A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol (2011) 0.85
Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Eur J Clin Pharmacol (2015) 0.85
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol (2003) 0.85
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci (2014) 0.84
YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs (2010) 0.84
A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One (2012) 0.84
CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol (2009) 0.83
Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res (2011) 0.83
Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics (2015) 0.83
ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. Br J Clin Pharmacol (2008) 0.83
Drug-induced trafficking of p-glycoprotein in human brain capillary endothelial cells as demonstrated by exposure to mitomycin C. PLoS One (2014) 0.82
Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone. PLoS One (2013) 0.82
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol (2006) 0.82
Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head. Acta Orthop (2009) 0.82
Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res (2012) 0.82
Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.81
Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res (2010) 0.81
Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm Res (2009) 0.81
Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One (2013) 0.81
Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations. Infect Genet Evol (2009) 0.81
ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One (2014) 0.81
MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results. Med Sci Monit (2015) 0.81
Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol Int (2011) 0.80
ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol Neurodegener (2006) 0.80
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol (2010) 0.80
MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br J Clin Pharmacol (2008) 0.80
Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J (2009) 0.80
Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics (2014) 0.79
Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol (2009) 0.78
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett (2014) 0.78
Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clin Pharmacol Ther (2015) 0.78
The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians. Cytotechnology (2014) 0.78
A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther (2008) 0.78
Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology (Berl) (2010) 0.78
Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol (2005) 0.78
ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. J Cancer Res Clin Oncol (2012) 0.78
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol (2007) 0.78
MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. BMC Gastroenterol (2013) 0.78
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J (2015) 0.78
ABCB1 polymorphisms associated with osteonecrosis of the femeral head. Int J Clin Exp Pathol (2015) 0.78
Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China. Acta Pharmacol Sin (2012) 0.78
Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? Am J Cancer Res (2016) 0.78
Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. Br J Clin Pharmacol (2015) 0.77
Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer. Pak J Med Sci (2013) 0.77
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A (2002) 13.83
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
Quorum sensing and Chromobacterium violaceum: exploitation of violacein production and inhibition for the detection of N-acylhomoserine lactones. Microbiology (1997) 7.83
Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science (1999) 7.51
Development of Internet-based multimedia applications. Trends Biochem Sci (1999) 7.34
Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J (1996) 6.36
Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev (1996) 6.01
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis (2006) 5.20
Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun (2003) 5.11
How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol Med (2009) 4.90
SOX9 directly regulates the type-II collagen gene. Nat Genet (1997) 4.88
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
Structure of chi hotspots of generalized recombination. Cell (1981) 4.19
MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry (2006) 4.16
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum (1997) 4.14
Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Violations of the international code of marketing of breast milk substitutes: prevalence in four countries. BMJ (1998) 3.57
Maternity services: the consumer's view. J R Coll Gen Pract (1986) 3.38
Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature (1999) 3.32
Unwinding and rewinding of DNA by the RecBC enzyme. Cell (1980) 3.30
Genetic evidence equating SRY and the testis-determining factor. Nature (1990) 3.22
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia (2005) 3.13
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
Mannheim intima-media thickness consensus. Cerebrovasc Dis (2004) 3.05
Morphogenic effects of alpha-factor on Saccharomyces cerevisiae a cells. J Bacteriol (1976) 3.02
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.81
Fatigue of maintained voluntary muscle contraction in man. J Physiol (1972) 2.76
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med (2001) 2.74
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest (1987) 2.70
A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol (2000) 2.70
Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J Virol (2001) 2.69
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
Cell interactions modulate embryonal carcinoma cell differentiation into parietal or visceral endoderm. Nature (1981) 2.62
The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature (1999) 2.61
Conservation. Reconsidering the consequences of selective fisheries. Science (2012) 2.57
High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther (2009) 2.54
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev (1999) 2.52
Deviation from developmentally appropriate self-care autonomy. Association with diabetes outcomes. Diabetes Care (1996) 2.51
In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45
RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J Virol (1992) 2.42
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem (2001) 2.42
Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology (2001) 2.34
Architectural DNA binding by a high-mobility-group/kinesin-like subunit in mammalian SWI/SNF-related complexes. Proc Natl Acad Sci U S A (1998) 2.30
Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics (2001) 2.29
The chromo superfamily: new members, duplication of the chromo domain and possible role in delivering transcription regulators to chromatin. Nucleic Acids Res (1995) 2.26
The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol (2000) 2.25
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Analysis of muscle receptor connections by spike-triggered averaging. 1. Spindle primary and tendon organ afferents. J Neurophysiol (1976) 2.20
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell 'culture shock' glycoprotein of Mr 43,000. EMBO J (1986) 2.18
Microsurgical replantation of the avulsed scalp: report of 20 cases. Plast Reconstr Surg (1996) 2.17
Computer navigation versus conventional total knee replacement: no difference in functional results at two years. J Bone Joint Surg Br (2007) 2.15
Turtle-associated salmonellosis. I. An estimation of the magnitude of the problem in the United States, 1970-1971. Am J Epidemiol (1972) 2.15
DNA array studies demonstrate convergent regulation of virulence factors by Cph1, Cph2, and Efg1 in Candida albicans. J Biol Chem (2001) 2.14
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest (1992) 2.11
Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol (2006) 2.06
Analysis of muscle receptor connections by spike-triggered averaging. 2. Spindle group II afferents. J Neurophysiol (1976) 2.03
Neighborhood deprivation affects children's mental health: environmental risks identified in a genetic design. Psychol Sci (2000) 2.02
Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. Proc Natl Acad Sci U S A (2000) 2.02
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999) 2.02
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Studies on the biosynthesis of laminin by murine parietal endoderm cells. Eur J Biochem (1981) 1.99
Reconstitution of transcription factor SL1: exclusive binding of TBP by SL1 or TFIID subunits. Science (1994) 1.98
Report of the Radionuclides in Nephrourology Committee on renal clearance. J Nucl Med (1996) 1.98
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1985) 1.97
Human TAFII 105 is a cell type-specific TFIID subunit related to hTAFII130. Cell (1996) 1.96
The R gene product of bacteriophage lambda is the murein transglycosylase. Mol Gen Genet (1981) 1.95
Augmentation of deglutitive upper esophageal sphincter opening in the elderly by exercise. Am J Physiol (1997) 1.89
Nucleotide sequence of the lysozyme gene of bacteriophage T4. Analysis of mutations involving repeated sequences. J Mol Biol (1983) 1.89
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
TATA box-binding protein (TBP)-related factor 2 (TRF2), a third member of the TBP family. Proc Natl Acad Sci U S A (1999) 1.86
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
Time to listen: a review of methods to solicit patient reports of adverse events. Qual Saf Health Care (2010) 1.84
Female streetworker--prostitutes in Glasgow: a descriptive study of their lifestyle. AIDS Care (1993) 1.80
Factors affecting the use of folic acid supplements in pregnant women in Glasgow. Br J Gen Pract (1997) 1.79
Randomized, controlled trial of behavior therapy for families of adolescents with insulin-dependent diabetes mellitus. J Pediatr Psychol (2000) 1.79
Blood and urine gold levels during chrysotherapy for rheumatoid arthritis. Rheumatol Rehabil (1975) 1.79
Use of human hepatocytes to study P450 gene induction. Methods Enzymol (1996) 1.79
Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther (1998) 1.79
A protein with several possible membrane-spanning domains encoded by the Drosophila segment polarity gene patched. Nature (1989) 1.77
SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein. Genes Dev (1996) 1.76
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology (2005) 1.75
Implementation of national diabetes retinal screening programme is associated with a lower proportion of patients referred to ophthalmology. Diabet Med (2005) 1.75